Edgar Filing: BIOGEN IDEC INC. - Form 4

Form 4										
WashingtoCheck this boxif no longersubject toSection 16.Form 4 orForm 5obligationsmay continuemay continue				IES AND EXCHANGE COMMISSIngton, D.C. 20549 ES IN BENEFICIAL OWNERSHIP (ECURITIES)) of the Securities Exchange Act of 193 y Holding Company Act of 1935 or Sec tment Company Act of 1940				OMB Number: Expires: Estimated a burden hour response	•	
SCANGOS GEORGE A Symbol			er Name and Ticker or Trading				5. Relationship of Reporting Person(s) to Issuer			
(Last) (First) (Middle) 3. Date o			of Earliest Transaction Day/Year) 2015				(Check all applicable) X Director 10% Owner X Officer (give title Other (specify below) Chief Executive Officer			
CAMBRID	(Street) OGE, MA 02142		endment, D onth/Day/Yea	-	al	-	5. Individual or Joi Applicable Line) _X_ Form filed by O Form filed by M Person	ne Reporting Per	rson	
(City)	(State)	(Zip) Tab	ole I - Non-l	Derivative	e Secu		ired, Disposed of,	or Beneficial	v Owned	
1.Title of Security2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, any		2A. Deemed Execution Date, if	3. 4. Securities Acquired (A Transaction Disposed of (D) Code (Instr. 3, 4 and 5) (Instr. 8) (A) or			cquired (A) (D) 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
Common Stock	03/13/2015		S <u>(1)</u>	Amount 537	(D) D	Price \$ 412.688 (2) (3)	45,176	D		
Common Stock							5,378	Ι	by Trust	
Common Stock							5,378	Ι	by Trust	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of
information contained in this form are not
required to respond unless the formSEC 1474
(9-02)

Edgar Filing: BIOGEN IDEC INC. - Form 4

displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	4. Transactio Code (Instr. 8)	5. orNumber of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	5	Date	7. Title Amoun Underly Securit (Instr. 3	nt of lying	8. Price of Derivative Security (Instr. 5)	9. Nu Deriv Secu Bene Owno Follo Repo Trans (Instr
			Code V		Date Exercisable	Expiration Date	Title I	Amount or Number of Shares		

Reporting Owners

Reporting Owner Name / Address	Relationships						
	Director	10% Owner	Officer	Other			
SCANGOS GEORGE A BIOGEN IDEC INC. 225 BINNEY STREET CAMBRIDGE, MA 02142	Х		Chief Executive Officer				
Signatures							

/s/ Matthew S. Gilman, Attorney in Fact for George A. Scangos

**Signature of Reporting Person

03/16/2015

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Sale pursuant to a trading plan intended to comply with Rule 10b5-1 of the Securities Exchange Act of 1934.
- (2) Full information regarding the number of shares sold at each separate price will be provided upon request by the SEC staff, the issuer, or a security holder of the issuer.
- (3) This represents the weighted average price for shares sold at a range between \$412.63 (low) and \$412.76 (high).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.